wuxiapptec.com Open in urlscan Pro
47.111.33.220  Public Scan

Form analysis
1 forms found in the DOM

#

<form action="#" class="search" data-v-f4a04f4c=""><label for="search1" data-v-f4a04f4c=""><img
      src="data:image/svg+xml;base64,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"
      data-v-f4a04f4c=""><span data-v-f4a04f4c=""></span></label><input id="search1" type="search" value="" class="search-input" data-v-f4a04f4c=""></form>

Text Content

Contact UsEN简繁
About Us
Services
Platform
News
Careers
Investors


WUXI APPTEC


GLOBAL PLATFORM
ONE VISION




OUR VISION


EVERY DRUG CAN BE MADE
AND EVERY DISEASE CAN BE TREATED

By Building an Open-access Platform with the Most Comprehensive Capabilities and
Technologies in the Global Healthcare Industry


OUR VALUES


INTEGRITY & DEDICATION, WORKING TOGETHER & SHARING SUCCESS;
DOING THE RIGHT THING, DOING IT RIGHT.








OVERVIEW


ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG)

View ESG Video



ABOUT US


ENABLING INNOVATION

As a global company with operations across Asia, Europe, and North America, WuXi
AppTec provides a broad portfolio of R&D and manufacturing services that enable
the global pharmaceutical and life sciences industry to advance discoveries and
deliver groundbreaking treatments to patients. Through its unique business
models, WuXi AppTec’s integrated, end-to-end services include chemistry drug
CRDMO (Contract Research, Development and Manufacturing Organization), biology
discovery, preclinical testing and clinical research services, advanced
therapies CTDMO (Contract Testing, Development and Manufacturing Organization),
helping customers improve the productivity of advancing healthcare products
through cost-effective and efficient solutions. WuXi AppTec received an AA ESG
rating from MSCI for the third consecutive year in 2023 and its open-access
platform is enabling more than 6,000 customers from over 30 countries to improve
the health of those in need – and to realize the vision that "every drug can be
made and every disease can be treated."

SEE MORE


SERVICES AND SOLUTIONS


AN OPEN ENABLING PLATFORM

Enabling more than 6,000 innovative customers from more than 30 Countries



Small Molecule Drug R&D and Manufacturing

Cell Therapy
and Gene Therapy

Drug R&D and Medical
Device Testing

Clinical
Services



Small Molecule Drug R&D and Manufacturing


COMPANY PLATFORM


ENABLING ANYONE, ANY COMPANY

To Become the Most Comprehensive Capability and Technology Platform in the
Global Pharmaceutical and Healthcare Industry


WUXI CHEMISTRY

Provides CRDMO services
for new drug development from discovery to commercial

SEE MORE


WUXI BIOLOGY

A full spectrum of biology services and solutions
supporting stand-alone and integrated projects

SEE MORE


WUXI TESTING

Seamless drug and medical device testing services
from preclinical testing to clinical trials

SEE MORE


WUXI ADVANCED THERAPIES

Global CTDMO
offering an integrated end-to-end solution to accelerate time to market for cell
and gene therapies

SEE MORE



NEWS


THE LATEST NEWS ABOUT WUXI APPTEC



WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges,
Maintaining Stable Operations

WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net
Profit Exceeded RMB10 Billion for the First Time

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™
(lifileucel) for Advanced Melanoma

WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing
API Manufacturing Site

WuXi AppTec Named 2023 Global Contract Research, Development and Manufacturing
Organization Company of the Year by Frost & Sullivan

WuXi AppTec Continued Solid Growth in the First Three Quarters of 2023 on Top of
an Exceptionally Strong Year in 2022, with Profit Growth Continuously Exceeding
Revenue Growth


WUXI APPTEC ACHIEVED FIRST QUARTER 2024 TARGET DESPITE EXTERNAL CHALLENGES,
MAINTAINING STABLE OPERATIONS

(SHANGHAI, April 29, 2024) — WuXi AppTec (stock code: 603259.SH / 2359.HK), a
global company that provides a broad portfolio of R&D and manufacturing services
that enable companies in the pharmaceutical and life sciences industry, today
announced its financial results for the first quarter ending March 31, 2024
(“Reporting Period”):

Read more


WUXI APPTEC REVENUE SURPASSED RMB40 BILLION IN 2023, AND ADJUSTED NON-IFRS NET
PROFIT EXCEEDED RMB10 BILLION FOR THE FIRST TIME

(SHANGHAI, March 18, 2024) — WuXi AppTec (stock code: 603259.SH / 2359.HK), a
global company that provides a broad portfolio of R&D and manufacturing services
that enable companies in the pharmaceutical and life sciences industry, today
announced its financial results for the year ending December 31, 2023
(“Reporting Period”)

Read more


WUXI ADVANCED THERAPIES RECEIVES FDA APPROVAL TO MANUFACTURE IOVANCE'S AMTAGVI™
(LIFILEUCEL) FOR ADVANCED MELANOMA

PHILADELPHIA, PA. February 20, 2024 – WuXi Advanced Therapies (WuXi ATU), a
wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and
Drug Administration (FDA) has approved its Philadelphia site to begin the
analytical testing and manufacturing of AMTAGVI for Iovance, which received FDA
accelerated approval of its Biologics License Application (BLA) on February 16,
2024.

Read more


WUXI APPTEC TRIPLES PEPTIDE MANUFACTURING CAPACITY AND LAUNCHES THE NEW TAIXING
API MANUFACTURING SITE

Shanghai, China - January 8, 2024 -- WuXi AppTec, a global company that provides
a broad portfolio of R&D and manufacturing services that enable companies in the
pharmaceutical, biotech and medical device industries to advance discoveries and
deliver groundbreaking treatments to patients, announced the commissioning of
its two new peptide manufacturing plants, one at its Changzhou facility and
another at the new Taixing site in China. This significant expansion has
increased the company’s Solid-Phase Peptide Synthesis (SPPS) total reactor
volume to 32,000 liters, addressing the surging global demand for peptide
therapeutics.

Read more


WUXI APPTEC NAMED 2023 GLOBAL CONTRACT RESEARCH, DEVELOPMENT AND MANUFACTURING
ORGANIZATION COMPANY OF THE YEAR BY FROST & SULLIVAN

SHANGHAI, November 8, 2023 – WuXi AppTec, a global company that provides a broad
portfolio of R&D and manufacturing services that enable companies in the
pharmaceutical, biotech and medical device industries to advance discoveries and
deliver groundbreaking treatments to patients, received the 2023 Global Contract
Research, Development and Manufacturing Organization Company of the Year Award
from Frost & Sullivan, a growth advisory & growth opportunity analytics firm.

Read more


WUXI APPTEC CONTINUED SOLID GROWTH IN THE FIRST THREE QUARTERS OF 2023 ON TOP OF
AN EXCEPTIONALLY STRONG YEAR IN 2022, WITH PROFIT GROWTH CONTINUOUSLY EXCEEDING
REVENUE GROWTH

(SHANGHAI, October 30, 2023) — WuXi AppTec (stock code: 603259.SH / 2359.HK), a
global company that provides a broad portfolio of R&D and manufacturing services
that enable companies in the pharmaceutical, biotech and medical device
industries to advance discoveries and deliver groundbreaking treatments to
patients, is pleased to announce its financial results for the third quarter and
nine months ended September 30, 2023 (“Reporting Period”)

Read more




CAREERS


WELCOME TO


OUR TEAM

Become Part of Creating a Better Life

Join Us


INVESTORS


THE LATEST FINANCIAL REPORTS, ANNOUNCEMENTS AND RESOURCES



SEE MORE


CONTACT US




WUXI APPTEC MAIN OFFICES

288 Fute Zhong Road
Waigaoqiao Free Trade Zone
Shanghai 200131, China
Tel: +86 (21) 5046-1111
Fax: +86 (21) 5046-1000


ENQUIRIES

Tel: 400-820-0985 (Mainland China)
857-413-2800 (U.S.)
+86 (21) 2066-3734 (Global)
Email: wuxiconcierge@wuxiapptec.com


SOCIAL MEDIA


SEE OUR GLOBAL SITES

© 2020 WuXi AppTec
Terms of Use  |  Privacy Policy  |  Transparency in
Coverage  |  沪ICP备10016157号  |  沪公网安备31011502012242号
© 2020 WuXi AppTec
Terms of Use  |  Privacy Policy  |  Transparency in Coverage  |  沪ICP备10016157号
沪公网安备31011502012242号